Last reviewed · How we verify
NCT04623047
Infection Watch Study
trial in COVID-19 Respiratory Infection in 10,034 participants. Completed in 15 June 2024.
15 June 2024
Quick facts
| Lead sponsor | Duke University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 10,034 |
| Start date | 28 June 2023 |
| Primary completion | 15 June 2024 |
| Estimated completion | 15 June 2024 |
| Sites | 1 location across United States |
Conditions studied
- COVID-19 Respiratory Infection — all drugs for COVID-19 Respiratory Infection →
- Respiratory Syncytial Virus Infections — all drugs for Respiratory Syncytial Virus Infections →
- Rhinoviral Infections — all drugs for Rhinoviral Infections →
- Influenza Viral Infections — all drugs for Influenza Viral Infections →
Sponsor
Duke University
Who can join
18 and older, any sex, with COVID-19 Respiratory Infection or Respiratory Syncytial Virus Infections. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will reach out to patients who have undergone diagnostic testing for the following respiratory illnesses from January 1st, 2018 to July 9th, 2023: COVID-19, Influenza, Rhinovirus, and Respiratory Syncytial Virus. This study aims to develop a forecasting model to predict infection onset prior to symptom onset using wearable device data and known symptom onset and test dates.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04623047
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19 Respiratory Infection
Currently open trials in the same condition.
- NCT06950177 — Pancoronavirus Vaccine Study in Healthy Adults · Phase 1 · active not recruiting
- NCT06402318 — Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine · recruiting
- NCT05765396 — SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies · active not recruiting
- NCT05689034 — Multicenter Randomized Double-blind Placebo-controlled Study to Investigate Azvudine in Symptomatic Adults With COVID-19 · Phase 2, PHASE3 · recruiting
- NCT05562505 — Trial of Venovenous ECMO to De-Sedate, Extubate and Mobilise in Hypoxic Respiratory Failure · NA · recruiting
Other Duke University trials
Trials by the same sponsor.
- NCT07216456 — Vaginal Dilator Therapy After Pelvic Radiation · NA · not yet recruiting
- NCT07519317 — Dosing and Deployment Trial: A Home-based Optokinetic Treatment · NA · not yet recruiting
- NCT07275359 — Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations · Phase 1 · not yet recruiting
- NCT07216963 — The Community Paramedic Response and Overdose Outreach With Supportive Medical-Legal Services Study · NA · not yet recruiting
- NCT07459218 — IDEAS for Hope to Reduce Suicide Risk and Improve HIV Care Engagement in Tanzania · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04623047 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Duke University
- Last refreshed: 3 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04623047.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing